Scholarlink

<p>Osthole (OS), an active component of traditional Chinese herbal medicine, has demonstrated a wide range of pharmacological effects and potential therapeutic value. This study aimed to explore the role of OS in alleviating airway inflammation in asthma. Ovalbumin (OVA) was used to induce a C57BL/6&#xa0;J mouse asthma model. The mice were injected intraperitoneally with 15&#xa0;mg/kg or 40&#xa0;mg/kg OS. Serum IgE levels and lung inflammation were assessed; the inflammatory cell count in the BALF was determined using Wright‒Giemsa staining, and protein levels were measured by ELISA and Western blotting. Histopathological analysis of lung tissue was conducted using HE and PAS staining. OS effectively lowered IgE levels in mouse serum, reduced lung damage, and inhibited the infiltration of inflammatory cells and the proliferation of goblet cells in the lungs. Furthermore, OS reduced the number of inflammatory cells, eosinophils, and leukocytes in the BALF. With respect to cytokines, OS inhibited the levels of Th2 cytokines (IL-4, IL-5, and IL-13) and increased the levels of Th1 cytokines (IFN-γ and IL-2). Mechanistically, OS treatment inhibited activation of the HMGB1–RAGE/TLR4–NF-κB signaling pathway, thereby alleviating airway inflammation in asthma. These data suggest that OS may be a promising drug for alleviating airway inflammation in mice with bronchial asthma and provide potential molecular targets for the action of OS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Osthole attenuates airway inflammation in asthma by inhibiting the HMGB1–RAGE/TLR4–NF-κB signaling pathway

  • 期刊论文

  • 发表日期：

    2025年7月14日

查看全文
  • Yanli Li,
  • Yushan Zhou,
  • Dailing Yan,
  • Yunfeng Yang,
  • Yi Xiao

摘要

Osthole (OS), an active component of traditional Chinese herbal medicine, has demonstrated a wide range of pharmacological effects and potential therapeutic value. This study aimed to explore the role of OS in alleviating airway inflammation in asthma. Ovalbumin (OVA) was used to induce a C57BL/6 J mouse asthma model. The mice were injected intraperitoneally with 15 mg/kg or 40 mg/kg OS. Serum IgE levels and lung inflammation were assessed; the inflammatory cell count in the BALF was determined using Wright‒Giemsa staining, and protein levels were measured by ELISA and Western blotting. Histopathological analysis of lung tissue was conducted using HE and PAS staining. OS effectively lowered IgE levels in mouse serum, reduced lung damage, and inhibited the infiltration of inflammatory cells and the proliferation of goblet cells in the lungs. Furthermore, OS reduced the number of inflammatory cells, eosinophils, and leukocytes in the BALF. With respect to cytokines, OS inhibited the levels of Th2 cytokines (IL-4, IL-5, and IL-13) and increased the levels of Th1 cytokines (IFN-γ and IL-2). Mechanistically, OS treatment inhibited activation of the HMGB1–RAGE/TLR4–NF-κB signaling pathway, thereby alleviating airway inflammation in asthma. These data suggest that OS may be a promising drug for alleviating airway inflammation in mice with bronchial asthma and provide potential molecular targets for the action of OS.